S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
S&P 500   4,280.15
DOW   33,761.05
QQQ   330.39
Sinema took Wall Street money while killing tax on investors
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Climate bill: Could coal communities shift to nuclear?
Shelling kills 1 in Ukraine; Russia wants nuke plant pledges
High oil prices help Saudi Aramco earn $88B in first half
Potential 500% Return From A Unique $1 Asset? (Ad)pixel
Former Deutsche Bank Co-CEO Anshu Jain dies
Ship carrying grain for hungry Ethiopia leaves Ukraine
'Everyone's Got a Story of How the Healthcare System Has Fallen Short.' This Founder Is on a Mission to Change That.
The Financial Day of Reckoning Has Begun (Ad)
NASDAQ:CRIS

Curis - CRIS Stock Forecast, Price & News

$1.15
+0.08 (+7.48%)
(As of 08/12/2022 12:00 AM ET)
Add
Compare
Today's Range
$1.06
$1.15
50-Day Range
$0.87
$1.30
52-Week Range
$0.70
$9.04
Volume
1.28 million shs
Average Volume
1.68 million shs
Market Capitalization
$105.39 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.67

Curis MarketRank™ Forecast

Analyst Rating
Moderate Buy
2.67 Rating Score
Upside/​Downside
740.6% Upside
$9.67 Price Target
Short Interest
Healthy
13.17% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.98mentions of Curis in the last 14 days
Based on 7 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.69) to ($0.64) Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

2.14 out of 5 stars

Medical Sector

536th out of 1,135 stocks

Biological Products, Except Diagnostic Industry

81st out of 180 stocks

CRIS stock logo

About Curis (NASDAQ:CRIS) Stock

Curis, Inc., a biotechnology company, engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial for the treatment of non-hodgkin lymphomas, and acute myeloid leukemia and myelodysplastic syndromes; and CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation. The company's pipeline also includes Fimepinostat, an oral dual inhibitor of HDAC and PI3K enzymes for the treatment of patients with MYC-altered diffuse large B-cell lymphoma; CA-170, an oral small molecule drug candidate for treating patients with advanced solid tumors and lymphomas; and CA-327, a pre-investigational new drug stage oncology drug candidate. It has collaboration agreement with F. Hoffmann-La Roche Ltd. and Genentech Inc. for the development and commercialization of Erivedge, an orally-administered small molecule hedgehog signaling pathway inhibitor for the treatment of advanced basal cell carcinoma; and with Aurigene Discovery Technologies Limited for the discovery, development, and commercialization of small molecule compounds in the areas of immuno-oncology and precision oncology. Curis, Inc. was incorporated in 2000 and is headquartered in Lexington, Massachusetts.

Analysts Set New Price Targets

Separately, StockNews.com raised Curis from a "sell" rating to a "hold" rating in a report on Thursday, May 12th.

Curis Price Performance

NASDAQ:CRIS traded up $0.08 on Friday, hitting $1.15. 1,275,657 shares of the stock were exchanged, compared to its average volume of 1,678,774. Curis has a 52-week low of $0.70 and a 52-week high of $9.04. The company has a market capitalization of $105.39 million, a price-to-earnings ratio of -1.85 and a beta of 2.66. The company's 50-day moving average price is $1.06 and its two-hundred day moving average price is $1.70.

Curis (NASDAQ:CRIS - Get Rating) last posted its quarterly earnings data on Thursday, August 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Curis had a negative net margin of 533.89% and a negative return on equity of 68.41%. During the same quarter in the previous year, the business posted ($0.12) EPS. Equities analysts predict that Curis will post -0.69 EPS for the current fiscal year.

Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

CRIS Stock News Headlines

Reviewing Editas Medicine (NASDAQ:EDIT) and Curis (NASDAQ:CRIS)
Curis (CRIS) Q2 2022 Earnings Call Transcript
Curis (CRIS) Reports Q2 Loss, Tops Revenue Estimates
See More Headlines
Receive CRIS Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Curis and its competitors with MarketBeat's FREE daily newsletter.

CRIS Company Calendar

Last Earnings
8/04/2022
Today
8/14/2022
Next Earnings (Estimated)
11/08/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Sector
Medical
Current Symbol
NASDAQ:CRIS
CUSIP
23126910
Employees
60
Year Founded
2000

Price Target and Rating

Average Stock Price Forecast
$9.67
High Stock Price Forecast
$15.00
Low Stock Price Forecast
$4.00
Forecasted Upside/Downside
+740.6%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.67
Research Coverage
3 Analysts

Profitability

Net Income
$-45,440,000.00
Net Margins
-533.89%
Pretax Margin
-533.89%

Debt

Sales & Book Value

Annual Sales
$10.65 million
Book Value
$0.68 per share

Miscellaneous

Free Float
85,954,000
Market Cap
$105.39 million
Optionable
Optionable
Beta
2.66

Social Links















CRIS Stock - Frequently Asked Questions

Should I buy or sell Curis stock right now?

3 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Curis in the last year. There are currently 1 hold rating and 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" CRIS shares.
View CRIS analyst ratings
or view top-rated stocks.

What is Curis' stock price forecast for 2022?

3 Wall Street research analysts have issued 1 year price targets for Curis' shares. Their CRIS share price forecasts range from $4.00 to $15.00. On average, they anticipate the company's share price to reach $9.67 in the next year. This suggests a possible upside of 740.6% from the stock's current price.
View analysts price targets for CRIS
or view top-rated stocks among Wall Street analysts.

How have CRIS shares performed in 2022?

Curis' stock was trading at $4.76 at the start of the year. Since then, CRIS shares have decreased by 75.8% and is now trading at $1.15.
View the best growth stocks for 2022 here
.

When is Curis' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, November 8th 2022.
View our CRIS earnings forecast
.

How were Curis' earnings last quarter?

Curis, Inc. (NASDAQ:CRIS) released its quarterly earnings results on Thursday, August, 4th. The biotechnology company reported ($0.17) earnings per share for the quarter, hitting the consensus estimate of ($0.17). Curis had a negative trailing twelve-month return on equity of 68.41% and a negative net margin of 533.89%. During the same period in the prior year, the company earned ($0.12) EPS.

When did Curis' stock split?

Curis's stock reverse split on Wednesday, May 30th 2018. The 1-5 reverse split was announced on Tuesday, May 22nd 2018. The number of shares owned by shareholders was adjusted after the market closes on Tuesday, May 29th 2018. An investor that had 100 shares of stock prior to the reverse split would have 20 shares after the split.

What other stocks do shareholders of Curis own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Curis investors own include Rite Aid (RAD), Celldex Therapeutics (CLDX), Micron Technology (MU), Novavax (NVAX), CTI BioPharma (CTIC), Nabriva Therapeutics (NBRV), Amarin (AMRN), Idera Pharmaceuticals (IDRA), ImmunoGen (IMGN) and OPKO Health (OPK).

What is Curis' stock symbol?

Curis trades on the NASDAQ under the ticker symbol "CRIS."

Who are Curis' major shareholders?

Curis' stock is owned by a number of retail and institutional investors. Top institutional investors include Renaissance Technologies LLC (2.61%), Russell Investments Group Ltd. (0.56%), Focused Wealth Management Inc (0.45%), Affinity Asset Advisors LLC (0.37%), Northern Trust Corp (0.18%) and LPL Financial LLC (0.10%).
View institutional ownership trends
.

How do I buy shares of Curis?

Shares of CRIS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Curis' stock price today?

One share of CRIS stock can currently be purchased for approximately $1.15.

How much money does Curis make?

Curis (NASDAQ:CRIS) has a market capitalization of $105.39 million and generates $10.65 million in revenue each year. The biotechnology company earns $-45,440,000.00 in net income (profit) each year or ($0.62) on an earnings per share basis.

When was Curis founded?

Curis was founded in 2000.

How can I contact Curis?

Curis' mailing address is 128 Spring Street Building C - Suite 500, LEXINGTON MA, 02421. The official website for the company is www.curis.com. The biotechnology company can be reached via phone at (617) 503-6500, via email at info@curis.com, or via fax at 617-503-6501.

This page (NASDAQ:CRIS) was last updated on 8/14/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.